Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2; no impact on study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T18:06:42.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Removal of the government funding operating-status banner from the page; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T17:54:49.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page shows a visual redesign; core study details, eligibility criteria, and outcomes remain unchanged.
    Difference
    0.5%
    Check dated 2025-11-03T12:39:23.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    6%
    Check dated 2025-10-05T17:27:17.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Upgrade version from v3.0.2 to v3.1.0; no other content changes are specified.
    Difference
    0.1%
    Check dated 2025-09-28T10:14:32.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.
    Difference
    0.4%
    Check dated 2025-09-14T00:22:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.